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Patterns of hepatitis C prevalence and seroconversion in
hemodialysis units from three continents: The DOPPS.
Background. Hepatitis C virus (HCV) remains a problem
within hemodialysis units. This study measures HCV prevalence
and seroconversion rates across seven countries and investi-
gates associations with facility-level practice patterns.
Methods. The study sample was from the Dialysis Outcomes
and Practice Patterns Study (DOPPS), a prospective, observa-
tional study of adult hemodialysis patients randomly selected
from 308 representative dialysis facilities in France, Germany,
Italy, Japan, Spain, the United Kingdom, and the United States.
Logistic regression was used to model odds of HCV prevalence,
and Cox regression was used to model time from study entry to
HCV seroconversion.
Results. Mean HCV facility prevalence was 13.5% and varied
among countries from 2.6% to 22.9%. Increased HCV preva-
lence was associated with longer time on dialysis, male gen-
der, black race, diabetes, hepatitis B (HBV) infection, prior
renal transplant, and alcohol or substance abuse in the pre-
vious 12 months. Approximately half of the facilities (55.6%)
had no seroconversions during the study period. HCV sero-
conversion was associated with longer time on dialysis, human
immunodeficiency virus/acquired immunodeficiency syndrome
(HIV/AIDS), HBV infection, and recurrent cellulitis or gan-
grene. An increase in highly trained staff was associated with
lower HCV prevalence (OR = 0.93 per 10% increase, P = 0.003)
and risk of seroconversion (RR = 0.92, P = 0.07). Seroconver-
sion was associated with an increase in facility HCV prevalence
(RR = 1.36, P < 0.0001), but not with isolation of HCV-infected
patients (RR = 1.01, P = 0.99).
Conclusion. There are differences in HCV prevalence and
rate of seroconversion at the country and the hemodialysis fa-
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cility level. The observed variation suggests opportunities for
improved HCV outcomes.
Hepatitis C virus (HCV) infection is a persistent public
health concern in hemodialysis patients [1, 2]. Hemodial-
ysis patients are vulnerable to HCV infection because of
the risk for exposure to HCV associated with the dialy-
sis procedure [3–5]. In contrast with the hepatitis B virus
(HBV), no vaccine is available for HCV [6]. Accurate
testing for HCV is complicated by regional variation in
the HCV genome and by variation in screening tests [4–7].
Patients infected with HCV often have minimal clinical
evidence of disease [5, 6, 8]. HCV infection in end-stage
renal disease (ESRD) patients has been associated with
greater morbidity and mortality [5, 9, 10]. HCV infection
has also been associated with greater morbidity and mor-
tality in ESRD patients after they have received a renal
transplant [11–13].
Infection control measures have been developed to re-
duce risk for transmission of blood-borne viruses within
the ESRD population. These measures include proto-
cols for handling body fluids, isolation policies, and use
of erythropoietin to minimize blood transfusions [5, 14].
However, HCV persists within hemodialysis units. Fur-
thermore, there is variation in HCV prevalence and
seroconversion rates between hemodialysis units [15].
Differences in patient behavior and community expo-
sures, such as intravenous drug abuse, may contribute
to persistence of HCV in hemodialysis units and also to
variation in HCV prevalence and seroconversion among
units. Application of infection control protocols also may
differ among units. It is likely that facility-level practice
patterns affect HCV transmission in dialysis units, even
in the current environment of infection control measures.
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HCV prevalence and seroconversion in the ESRD
population have been examined in several country and
region-specific studies [abstract; Barril G, et al, Nephrol
Dial Transplant 15:A107, 2000] [5, 16]. Worldwide, uni-
formly collected statistics on prevalence and serocon-
version of HCV in hemodialysis units do not exist.
The present study used data from the Dialysis Out-
comes and Practice Patterns Study (DOPPS) to deter-
mine HCV prevalence and seroconversion rates in seven
countries and to investigate whether facility-level prac-
tice patterns were associated with HCV prevalence and
seroconversion.
METHODS
Data sources
This study used a sample of 8615 hemodialysis pa-
tients from the DOPPS, a prospective, observational
study involving adult hemodialysis patients randomly se-
lected from 308 representative dialysis facilities in France,
Germany, Italy, Japan, Spain, the United Kingdom, and
the United States. Facilities in the United States started
the study in 1997; European facilities began in 1998, and
Japanese units in 1999. This analysis used longitudinal
data gathered through spring 2001. The DOPPS sampling
plan and study methods have been described elsewhere
[17].
Classification of HCV status
Classification of HCV status was based on clinical his-
tory from patients and their health care providers and on
serum HCV antibody status. The DOPPS did not collect
information on other diagnostic methods for HCV status,
such as polymerase chain reaction (PCR).
A case of HCV was defined as a patient who had a his-
tory of HCV diagnosis or who was HCV antibody positive
at the time of entry into the study. Answers given by the
DOPPS study coordinator in each hemodialysis center to
the question, “Diagnosis of hepatitis C on or before the
enrollment date? [possible choices—yes, no, suspected]”
were combined with serology results to define HCV clas-
sification. After initial entry into the study, updates on
HCV antibody status were requested every 4 months. A
new case of HCV infection was defined as seroconver-
sion by a patient from HCV antibody negative at initial
testing to HCV antibody positive in the reporting center
during the study period.
HCV prevalence
For 6722 out of 8615 patients (78%), answers to the
clinical history question and serology results at study en-
try did not conflict and gave a clear HCV classification
of either positive or negative. For 42 patients, the ques-
tion, “Diagnosis of hepatitis C,” was answered “yes,” and
the patient was noted to be HCV antibody negative. As
HCV antibody may disappear with convalescence or be
absent in immunocompromised patients, these patients
were classified as HCV positive. Another 41 patients had
a positive history of HCV but no antibody test to confirm
that history. They, too, were classified as HCV positive.
There were 33 patients for whom the question, “Diagno-
sis of hepatitis C,” was answered “suspected.” For 19 of
these patients, HCV antibody was positive and the pa-
tients were classified HCV positive. For seven of these
patients, HCV antibody was negative and the patients
were classified HCV negative. For the remaining seven
patients with a suspected history of HCV, HCV antibody
was unknown and the patients were excluded from the
analysis. For 1099 patients, the question, “Diagnosis of
hepatitis C,” was answered “no,” and HCV antibody was
unknown or missing. These patients were excluded from
the analysis. An additional 719 patients were missing a
response to “history of hepatitis C” and had an unknown
or missing HCV antibody serology. These patients were
also excluded from the analysis.
HCV seroconversion
Inclusion in the HCV seroconversion analysis required
both a baseline HCV serology and a follow-up HCV
serology. Patients with only a baseline serology were
excluded from the analysis (N = 726). Removal of pa-
tients from the analysis resulted in removal of hemodial-
ysis units from the analysis. After exclusion of those
hemodialysis units that had no patients with both a base-
line and a follow-up HCV serology, the number of units
that remained per number of units sampled by country
were France 19/20, Germany 20/21, Italy 20/20, Japan
64/65, Spain 20/20, United Kingdom 19/20, and United
States 97/142. The average patient characteristics (age,
race, gender, and 17 comorbidities) of units that were
excluded from the analysis were compared with average
patient characteristics of units that remained in the anal-
ysis, using two-sample t tests.
Statistical methods
The main outcome variables of interest were HCV
prevalence at study start and HCV antibody seroconver-
sion rates. HCV seroconversion rates were calculated as
the number of conversions per 100 patient-years of ob-
servation. Independent variables included country, pa-
tient demographics (age, gender, and race), years on
ESRD, reported history of alcohol or substance abuse
in the past 12 months, and a history of any of the follow-
ing conditions: prior transplant, HBV positive, coronary
artery disease, congestive heart failure (CHF), cardiac
disease other than CHF, hypertension, diabetes, cere-
brovascular disease, peripheral vascular disease (PVD),
cancer, HIV/AIDS, lung disease, neurologic disorders,
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psychiatric disease, and gastrointestinal bleed. Informa-
tion on substance abuse was obtained by asking the ques-
tion, “Does the patient have a history of substance abuse
within the past 12 months?” The question did not specifi-
cally ask about different types of drugs or different routes
of administration. Information about alcohol was ob-
tained in a separate question, “Does the patient have a
history of alcohol abuse within the past 12 months?”
Confidence intervals for adjusted prevalence and se-
roconversion measures of association were constructed
for each county. The confidence intervals can be used for
interpretation for each individual country, although the
significance of differences between countries cannot be
inferred based on confidence interval overlap.
Practice pattern analysis
Associations among the facility prevalence of HCV
infection and facility practice patterns were examined
using logistic regression, with results presented using
adjusted odds ratios (OR). Associations between facil-
ity practice patterns and time to HCV seroconversion
were examined using Cox proportional hazards re-
gression. Facility characteristics and practice patterns
modeled as predictor variables included facility HCV
prevalence, presence of a protocol for HCV-infected
patients, treatment of HCV-infected patients at an iso-
lation station, treatment of HBV-infected patients at
an isolation station, facility screening for HCV at least
yearly, number of isolation stations (per increase by one
station), patients per station (per one unit increase),
routine administration of HBV vaccine, ratio of
physician-to-patient interaction time (physician min-
utes/patient minutes/per month), patient-to-staff ratio
(patient hours/staff hours), highly trained staff (per 10%
increase in highly trained staff), experienced direct pa-
tient care staff (per 10% increase), inexperienced di-
rect patient care staff (per 10% increase), whether the
hemodialysis facility treated patients with acute renal fail-
ure, whether the facility was hospital-based, facility size
(number of patients), and policy of dialyzer reuse.
The DOPPS questionnaire did not query whether iso-
lation stations were located in a room separate from other
dialysis stations. Highly trained staff members were de-
fined as those who had received at least 2 years of formal
nursing training. Experienced staff were defined as those
nurses who had worked for 3 years or more in the dial-
ysis unit of interest, and inexperienced staff were those
who had worked for less than 1 year in the dialysis unit of
interest. The DOPPS questionnaire did not collect infor-
mation on length or type of nursing experience prior to
employment in the dialysis unit of interest. These models
also were adjusted for the demographic characteristics
and comorbidities listed above, as well as for reported
substance or alcohol abuse and time since start of ESRD.
Table 1. Adjusted odds ratios for prevalence and adjusted risk ratio
for seroconversion of hepatitis C by patient characteristicsa
Patients % Odds ratio for Risk ratio for
or mean prevalence seroconversion
Measure (SD) (P value) (P value)
Ageb 59.9 (14.7) 0.97 (0.26) 1.00 (0.66)
Race
Black 17.4 1.93 (<0.0001) 1.42 (0.05)
Nonblack 82.6 1.00 (ref) 1.00 (ref)
Gender
Male 56.8 1.18 (0.01) 0.96 (0.74)
Female 43.2 1.00 (ref) 1.00 (ref)
Years on end-stage renal 4.94 (5.4) 1.13 (<0.0001) 1.04 (0.007)
disease (ESRD)
Comorbid conditions
Diabetes 33.0 1.18 (0.03) 1.07 (0.62)
Gastrointestinal bleed 6.9 1.22 (0.06) 1.45 (0.08)
Hepititis B virus 3.3 2.56 (<0.0001) 2.16 (0.001)
Prior renal transplant 6.8 1.34 (0.01) 0.95 (0.86)
Cancer 8.3 1.17 (0.10) 0.94 (0.77)
HIV/AIDS 0.6 1.67 (0.15) 3.29 (0.006)
Recurrent cellulitis/ 7.5 0.98 (0.86) 0.35 (0.004)
gangrene
Neurologic disease 8.4 1.14 (0.22) 1.35 (0.17)
Peripheral vascular 21.3 0.93 (0.45) 1.34 (0.06)
disease
Coronary artery 36.0 0.88 (0.09) 0.88 (0.36)
disease
Congestive heart 29.6 0.99 (0.96) 1.11 (0.51)
failure
Arrhythmia/other 33.2 1.09 (0.19) 0.90 (0.47)
cardiac disease
Hypertension 73.2 1.01 (0.91) 1.01 (0.95)
Cerebrovascular 15.5 1.06 (0.50) 1.01 (0.96)
disease
Lung disease 9.4 1.11 (0.38) 0.76 (0.26)
Psychiatric disease 18.9 1.03 (0.72) 0.99 (0.94)
Dyspnea 19.8 0.86 (0.09) 1.04 (0.82)
Substance abuse 1.70 2.44 (<0.0001) 1.63 (0.19)
Alcohol Abuse 3.04 1.75 (0.0001) 0.85 (0.63)
aAdjusted for patient characteristics at study entry: age, gender, race, country,
years on ESRD, alcohol abuse, and substance abuse in the past 12 months, and
17 comorbid conditions; bOR and RR are given for increments of 10 years.
For the logistic regression models, generalized estimat-
ing equations (GEE) were used to account for clustering
at the facility level, assuming a compound symmetry co-
variance structure [18]. For the Cox regression models,
robust variance estimates (the sandwich estimator) were
used to account for clustering at the facility level [19].
All analyses were performed using the SAS Statistical
Package, version 8.2 (SAS Institute, Cary, NC, USA).
RESULTS
The initial sample included 8615 randomly selected
hemodialysis patients, treated in 308 dialysis facilities.
Table 1 summarizes the demographic and comorbid char-
acteristics of the patient sample. The mean and median
ages were 59.9 years and 62.0 years, respectively. Black
patients comprised 17.4% of the sample, and nonblack
patients 82.6%. The sample was 56.8% male. Comor-
bid conditions occurred frequently, consistent with other
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Table 2. Prevalence and seroconversion rates, by country
Adjusted
Adjusted Unadjusted seroconversions/100
Unadjusted prevalencea % seroconversions/100 patient-yearsa %
Country prevalence % (95% CI) patient-years % (95% CI)
France 14.7 10.4 (9.7–11.2) 1.9 2.0 (1.4–2.8)
Germany 3.9 3.8 (3.3–4.4) 1.7 1.7 (1.2–2.5)
Italy 22.2 20.5 (19.4–21.7) 3.6 3.9 (2.9–5.2)
Japan 19.9 14.8 (14.0–15.6) 3.1 3.0 (2.3–3.9)
Spain 22.2 22.9 (21.7–24.1) 3.0 3.5 (2.5–4.8)
United Kingdom 2.7 2.6 (2.1–3.2) 1.1 1.2 (0.7–2.0)
United States 14.4 14.0 (13.6–14.5) 3.1 2.5 (2.1–2.9)
aAdjusted for the average of each of the following patient characteristics: age, gender, race, time on end-stage renal disease (ESRD), and alcohol or drug abuse in
the past 12 months.
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Fig. 1. Variation in hepatitis C virus (HCV)
prevalence by patient’s time with end-stage re-
nal disease (ESRD). The mean time on ESRD
was 4.9 years, with a standard deviation of 5.4
years.
studies. Substance abuse, a potential risk factor for HCV,
was noted in 1.7% of the sample.
HCV prevalence
Table 1 shows associations between HCV prevalence
and patient demographic and comorbid characteristics.
Age was not significantly associated with prevalence of
HCV infection. Black race was associated with a large and
significantly higher risk for prevalence of HCV (OR =
1.93, P < 0.0001). Male gender was also associated with
increased HCV prevalence (OR = 1.18, P = 0.01). HCV
was more prevalent in those patients with diabetes mel-
litus (OR = 1.18, P = 0.03), with a history of gas-
trointestinal bleed (OR = 1.22, P = 0.06), with HBV
infection (OR = 2.56, P < 0.0001), and in patients with
a prior renal transplant (OR = 1.34, P = 0.01). Drug
and alcohol abuse, as reported for the 12 months prior to
data collection, were significantly associated with HCV
prevalence, with OR of 2.44 (P < 0.0001) and 1.75
(P = 0.0001), respectively.
Table 2 shows HCV prevalence by country with and
without adjustment for age, gender, race, and time on
ESRD. Both unadjusted and adjusted HCV prevalence
was higher in Italy, Japan, and Spain and lower in
Germany and the United Kingdom.
The pattern of prevalence of HCV by interval of time
on ESRD is shown in Figure 1. Prevalence among inci-
dent patients at 90 days after the start of ESRD was 7.3%.
Prevalence of HCV rose as years since onset of ESRD
increased. Time on ESRD therapy was significantly as-
sociated with HCV prevalence, with a 13% higher odds
ratio of HCV prevalence per 1-year increase in ESRD
(Table 1) (AOR = 1.13 per year, P < 0.0001).
Figure 2 shows the distribution of HCV prevalence
among dialysis facilities. In the 308 facilities studied, the
mean HCV prevalence was 13.5%, with a median of
10.5%.
HCV seroconversion
The results of a sensitivity analysis comparing average
patient characteristics (age, race, gender, and 17 comor-
bidities) for excluded units with comparable characteris-
tics for units remaining in the analysis found no significant
differences.
Table 1 provides the adjusted risk ratio (RR) of HCV
seroconversion for a variety of demographic character-
istics and comorbid conditions. Seroconversion was not
significantly associated with age or gender. Seroconver-
sion was significantly associated with black race (RR =
1.42, P = 0.05). Duration of ESRD therapy by year was
associated with a 4% higher risk of seroconversion (P =
0.007). Diagnoses of HIV/AIDS or HBV infection were
both strongly and significantly associated with a higher
risk of seroconversion (RR = 3.29, P = 0.006 and RR
= 2.16, P = 0.001, respectively). A history of substance
abuse, as reported for the 12 months prior to data collec-
tion, was not significantly associated with HCV serocon-
version (RR = 1.63, P = 0.19). Alcohol abuse was also not
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significantly associated with HCV seroconversion (RR =
0.85, P = 0.63).
Table 2 provides HCV seroconversion rates by country,
unadjusted and after adjustment for age, gender, and race.
Both the unadjusted and adjusted seroconversion rates
were lower in the United Kingdom and Germany and
higher in Italy.
Figure 3 shows the facility distribution of HCV sero-
conversion rates for those facilities in which a seroconver-
sion rate could be calculated. In 55.6% of facilities there
were no seroconversions, while in the remaining 44.4%
of facilities the seroconversion rate ranged from >0% to
20%.
Practice patterns and facility characteristics
Table 3 gives the distribution of HCV testing frequency
as a percentage of units in each country. In this sample,
every unit from France reported routine testing at least
yearly, while 61.5% of units sampled in the United States
reported none.
Several practice patterns were evaluated for preva-
lence in the units sampled and also for association with
HCV prevalence and seroconversion (Table 4). Results
are shown for separate models (each practice pattern
modeled separately) and combined models (all prac-
tice patterns included in the model simultaneously).
All models were adjusted for patient characteristics.
Use of an isolation station for HCV patients was re-
Table 3. Distribution of hepatitis C virus (HCV) testing frequency by
percentage of units, in each country
Not
Monthly routinely
Country or more Quarterly Biannually Yearly done
France 5.0 15.0 60.0 20.0 0.0
Germany 0.0 10.5 57.9 15.8 15.8
Italy 16.7 27.8 38.9 5.6 11.1
Japan 3.1 9.2 0.0 52.3 35.4
Spain 0.0 27.8 44.4 5.6 22.2
United Kingdom 5.3 52.6 21.1 5.3 15.8
United States 8.4 13.3 0.0 16.8 61.5
ported in 11.8% of units. The mean facility size was 78
(SD = 51) patients per facility. HCV prevalence was
lower in facilities with a greater proportion of highly
trained staff in both the separate and the combined
models.
In the models for HCV seroconversion that examined
a single practice pattern, an increase in the number of
isolation stations was associated with lower HCV preva-
lence. Two additional practice patterns were associated
with lower HCV prevalence in the separate models, with
marginal statistical significance. These were isolation of
HBV patients and increase in highly trained staff. In the
combined models, number of isolation stations was no
longer associated with lower HCV prevalence. In the
combined models, both isolation of HBV patients and in-
crease in highly trained staff retained levels of association
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Table 4. Associations among practice patterns and cutcomesa
Prevalence odds ratio Seroconversion relative ratio
Facility mean Separate Combined Separate Combined
Practice pattern (SD) or % (yes) model modelb model modelb
Facility HCV prevalence (per 10%) 13.5 — — 1.42 (<0.0001)c 1.36 (<0.0001)c
Protocol for HCV-infected patients (yes/no) 83.9 1.11 (0.52) 1.16 (0.42) 0.74 (0.12) 0.80 (0.34)
Isolate HCV patients (yes/no) 11.8 0.74 (0.08) 0.76 (0.15) 0.79 (0.56) 1.01 (0.99)
Isolate HBV patients (yes/no) 50.8 0.99 (0.95) 1.17 (0.32) 0.66 (0.08) 0.63 (0.08)
Facility screens for HCV at least yearly (yes/no) 58.0 0.90 (0.41) 0.83 (0.15) 0.88 (0.50) 0.89 (0.54)
Number of isolation stations (per station) 1.2 (1.8) 1.01 (0.83) 0.96 (0.23) 0.89 (0.02)d 0.96 (0.46)
Patients/station (per one unit increase) 4.2 (2.1) 1.02 (0.52) 1.04 (0.38) 0.98 (0.73) 0.95 (0.53)
HBV vaccine routinely administered (yes/no) 63.9 0.95 (0.77) 0.85 (0.37) 0.99 (0.96) 0.86 (0.65)
Physician-patent interaction (min/month) 57 (83) 1.00 (0.51) 1.00 (0.14) 0.99 (0.06) 0.99 (0.37)
Patient hours/direct patient-staff hours 2.0 (0.7) 0.93 (0.53) 0.96 (0.71) 0.99 (0.91) 1.07 (0.56)
Highly trained staffe,f 58.1 0.95 (0.005)c 0.93 (0.003)c 0.92 (0.06) 0.92 (0.07)
% Experienced direct patient care stafff,g 60.9 1.01 (0.86) 1.03 (0.44) 0.96 (0.30) 0.99 (0.89)
% Inexperienced direct patient care stafff,h 17.1 1.02 (0.66) 1.03 (0.55) 1.07 (0.13) 1.07 (0.25)
Facility treats acute patients (yes/no) 59.7 0.99 (0.97) 1.06 (0.64) 1.14 (0.49) 1.18 (0.34)
Facility is hospital based (yes/no) 41.8 1.11 (0.42) 1.24 (0.13) 0.93 (0.65) 1.04 (0.85)
Facility size (per 10 patients) 78 (51) 1.01 (0.43) 0.99 (0.42) 0.99 (0.87) 0.99 (0.99)
Dialyzer reusei (yes/no) 80.2 0.88 (0.61) 0.75 (0.32) 0.70 (0.15) 0.66 (0.13)
Abbreviations are: HCV, hepatitis C virus; HBV, hepatitis B virus.
aAdjusted for patient level factors: age, gender, race, time on end-stage renal disease (ESRD), history of drug abuse, history of alcohol use, prior transplant, HBV
status, country of residence, and comorbid conditions.
bAll practice patterns included in the model simultaneously.
cP < 0.01; dP < 0.05; eHighly trained staff is defined as at least 2 years of formal nursing training; fPer 10% increase; gStaff has worked in facility for > 3 years; hStaff
has worked in facility < 1 year; iModel included only the three countries in DOPPS that reuse: the United States, Spain, and the United Kingdom.
and significance similar to levels in the separate models.
There was a strong and significant association between fa-
cility HCV prevalence and higher risk for seroconversion
in both the separate and the combined models. Isolation
of HCV-infected patients was not associated with lower
risk of seroconversion in either the separate or the com-
bined models.
HCV prevalence and HCV seroconversion were not
associated with yearly screening for HCV by the facil-
ity in either the separate or the combined models. HCV
prevalence and seroconversion also were modeled on the
smaller increments of HCV testing frequency shown in
Table 3. Again, no association was found between the
frequency of HCV testing and either HCV prevalence or
seroconversion.
DISCUSSION
This prospective study estimated HCV prevalence and
seroconversion rates in hemodialysis units in seven coun-
tries and evaluated associations between facility level
practice patterns and HCV prevalence and seroconver-
sion. HCV infection persists even in the current environ-
ment of infection control measures, and HCV outcomes
vary by patient characteristics, country, and hemodialysis
facility practice patterns.
The DOPPS estimates of HCV prevalence are similar
to published reports in the United States [1, 20], Italy
[21], Spain [abstract; Barril G et al, J Am Soc Nephrol
12:369A, 2001], Germany [14], France [22], and Japan
[23]. The DOPPS results are also in agreement with pub-
lished reports showing variation by hemodialysis unit and
country [24, 25]. It is likely that differences in the under-
lying prevalence of HCV infection in the general popula-
tion of these countries contributed to the differences we
observed [5, 26, 27].
HCV prevalence data are relatively easy to obtain and
already available for most countries in the DOPPS. In
contrast, HCV incidence data are more difficult to obtain,
and there are only a few published estimates of HCV se-
roconversion rates by country. When the DOPPS HCV
seroconversion rates are compared with existing conve-
nience samples spanning a similar time period, rates of
seroconversion for HCV for European countries in the
DOPPS are markedly higher [abstract; Barril G et al,
J Am Soc Nephrol 12:369A, 2001] [21, 28]. In studies
that specifically recruited hemodialysis units for HCV-
related studies, selection bias may influence results. Par-
ticipation of a hemodialysis unit in a study of HCV may
increase staff awareness of HCV and improve practice
patterns with regard to HCV and other blood-borne dis-
eases. The random selection of participating units in the
DOPPS sample may provide a better estimate of HCV
prevalence and seroconversion than previous European
samples chosen specifically for the study of HCV.
The positive association between HCV prevalence and
years on hemodialysis (Fig. 1) has been found in prior,
smaller studies [29, 30]. Patients on hemodialysis for
longer periods of time started treatment before routine
implementation of practice patterns such as donor blood
and graft screens for HCV antibodies, universal precau-
tions, and decreased blood transfusions associated with
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use of erythropoietin. It is also possible that patients who
have undergone hemodialysis for a longer period of time
have a longer time at risk for exposure to HCV than those
patients with a shorter amount of time on hemodialysis.
The DOPPS only collected data on the HCV antibody
tests and not results from other tests used by units to de-
termine HCV status. It is likely that the majority of units
used liver enzymes and HCV antibody to determine HCV
status. Multiple studies have verified that liver enzymes
and HCV antibody may be negative in the presence of
viremia [15, 31, 32]. Thus, it is likely that this analysis
underestimated HCV prevalence and seroconversion.
Our sample found large variation in frequency of test-
ing for HCV. Most notably, 61.5% of the United States
units sampled in the DOPPS reported that they did not
routinely test for HCV, in agreement with a recent United
States report that 42% of units sampled did not rou-
tinely test [20]. It is not clear whether frequency of HCV
screening is a clinically meaningful practice pattern. In
the DOPPS sample, neither HCV prevalence nor HCV
seroconversion was predicted by frequency of testing for
HCV. Furthermore, there were no significant differences
in the average patient characteristics between hemodial-
ysis units that were excluded from the analysis due to lack
of HCV reporting and those that remained.
Consensus regarding need for hemodialysis patient iso-
lation and dedicated dialysis machines to prevent HCV
transmission, in addition to blood-borne precautions,
does not exist in the nephrology community. Several in-
vestigators report that strict implementation of univer-
sal precautions is sufficient [33–35]. Other investigators
focus on isolation of HCV-positive patients and have
shown that nosocomial transmission of HCV decreased
after separation of HCV-positive patients [36] and that
hemodialysis units without isolation of HCV patients
have higher rates of HCV infection [37]. The large and
significant association between facility HCV prevalence
and HCV seroconversion in this study provides evidence
for nosocomial transmission. However, overall, this study
does not provide evidence that isolation of patients in-
fected with HCV is associated with decreased risk of
HCV seroconversion.
Although the result did not achieve statistical sig-
nificance, it is notable that isolation of HBV positive
patients was associated with smaller risk of HCV sero-
conversion. It is possible that hemodialysis staff members
in units that isolate HBV positive patients have a higher
level of attention to specific infection control procedures,
such as hand-washing and vigilance regarding blood
contamination.
This analysis evaluated associations between staffing
practice patterns at the hemodialysis facility level and
HCV outcomes. An increase in the percentage of highly
trained staff was significantly associated with decreased
prevalence and was also associated with decreased risk of
seroconversion at a level approaching significance. Fur-
thermore, there was a trend toward association between
an increase in experienced direct patient care staff and
decreased seroconversion in both the separate and com-
bined models. There was also a trend toward increased
risk for seroconversion with an increase in inexperienced
direct patient care staff in both the separate and the com-
bined practice pattern models. These results are consis-
tent with other studies that demonstrate decreased rates
of seroconversion with increased training for handling
of blood-borne diseases. Other studies also demonstrate
better hospital outcomes with a higher proportion of reg-
istered nurses directly involved in patient care [21, 38].
The lack of association between physician interaction
time with hemodialysis patients per month and HCV
prevalence or seroconversion is understandable, given
that the responsibility for carrying out infection control
measures mainly falls to the nursing staff.
Protocols to minimize virus transmission have been
in place in hemodialysis units for many years. Even so,
this random sample from seven countries demonstated
that HCV seroconversion persists within dialysis units.
This sample also demonstrated variation in implemen-
tation of infection control measures and differences in
HCV outcomes associated with facility-level practice pat-
terns. The observed persistence of HCV seroconversion
within dialysis units makes reexamination of infection
control practice patterns highly relevant. The observed
variation in practice patterns and outcomes suggests that
further clarification of optimal practice patterns at the fa-
cility level may provide opportunities for improved HCV
control.
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